Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics, Inc. Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties LEXINGTON, M...